VERU Reports Q3 Net Loss of $7.0M; Raises Going Concern Doubt
VERU Inc. reported a net loss of $7.0 million for the third quarter ended June 30, 2026, and a net loss of $15.1 million for the nine-month period. The company's management raised substantial doubt about its ability to continue as a going concern for the next twelve months, citing insufficient cash to fund operations. Despite this, cash and cash equivalents increased to $23.9 million, partly due to $23.4 million in proceeds from a public offering of common stock and warrants. The company continues to focus on developing its drug candidates, enobosarm and sabizabulin, with no net revenues from continuing operations.
Key Highlights
- Net loss for Q3 2026 was $7.0 million, compared to $7.3 million in Q3 2025.
- Net loss for the nine months ended June 30, 2026, was $15.1 million.
- Net loss per diluted share for Q3 2026 was $(0.30).
- Cash, cash equivalents, and restricted cash increased to $23.9 million.
- Net cash used in operating activities was $20.6 million for the nine months.
- Proceeds from a public offering totaled $23.4 million.
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Research and development expenses increased to $4.4 million in Q3 2026.
Price Impact
More from VERU
Veru Inc. Advances Sabizabulin for Pancreatic Cancer; Discontinues Inflammation Program
Veru Fully Enrolls PLATEAU Trial; Secures Enobosarm Patent to 2044
Veru Q3 Net Loss $7.0M; Enobosarm Trial Fully Enrolled; Patent Until 2044